4. Primary lateral sclerosis Clinical trials / Disease details

Clinical trials : 7 /  Drugs : 17 - (DrugBank : 9) / Drug target genes : 19 - Drug target pathways : 32

  
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04825613
(ClinicalTrials.gov)		June 1, 202125/3/2021Individual Patient Expanded Access IND to Treat Primary Lateral SclerosisIndividual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Primary Lateral SclerosisPrimary Lateral Sclerosis, Adult, 1Biological: HB-adMSCsHope Biosciences Stem Cell Research FoundationHope BiosciencesTemporarily not available18 YearsN/AMaleUnited States
2NCT03929068
(ClinicalTrials.gov)		May 13, 201910/4/2019Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral SclerosisSinemet in ALS and PLSAmyotrophic Lateral Sclerosis;Motor Neuron DiseaseDrug: carbidopa-levodopa;Drug: Placebo Oral TabletWashington University School of MedicineNULLEnrolling by invitation18 YearsN/AAll15Phase 1United States
3EUCTR2018-000142-18-FI
(EUCTR)		09/05/201808/05/2018Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative careFeasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care Amyotrophic lateral sclerosis (ALS)
MedDRA version: 20.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Dexdor
INN or Proposed INN: DEXMEDETOMIDINE
Trade Name: Ketanest-S
INN or Proposed INN: ESKETAMINE		Turku University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		20Phase 4Finland
4NCT03067857
(ClinicalTrials.gov)		September 201625/2/2017Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron DiseaseAutologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron DiseaseMotor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular Atrophy;Progressive Bulbar PalsiesBiological: Stem CellsStem Cells ArabiaNULLUnknown status24 Years70 YearsAll40Phase 1/Phase 2NULL
5NCT02868567
(ClinicalTrials.gov)		March 201617/3/2016Use of Dalfampridine in Primary Lateral SclerosisA Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral SclerosisMotor Neuron Disease, UpperDrug: dalfampridineWeill Medical College of Cornell UniversityHospital for Special Surgery, New YorkRecruiting18 Years99 YearsAll35Phase 1United States
6EUCTR2011-004798-99-DE
(EUCTR)		27/02/201327/12/2012Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS)Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS) - Pyrimethamine In Familial ALS Familial amyotrophic lateral sclerosis (FALS)
MedDRA version: 14.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: Daraprim
INN or Proposed INN: PYRIMETHAMINE		Weill Medical College of Cornell UniversityNULLNot RecruitingFemale: yes
Male: yes		40United States;Germany;Italy
7NCT00324454
(ClinicalTrials.gov)		May 20069/5/2006Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron DiseaseA Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron DiseaseMotor Neuron Disease;Amyotrophic Lateral Sclerosis;Primary Lateral Sclerosis;Progressive Muscular AtrophyBiological: LevetiracetamDuke UniversityUCB PharmaCompleted18 YearsN/ABoth20Phase 2United States

Back to top